SOLAR-1 trial: alpha-specific PI3K inhibitor Alpelisib has met primary endpoint in HR+/HER2- advanced breast cancer with PIK3CA mutation
The global phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor Alpelisib ( BYL719 ) has met the primary endpoint showing an improvement in progression-free survival ( ...
read article